An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial

INTRODUCTION: Arginase-1 (ARG1) and Programed death ligand-1 (PD-L1) play a vital role in immunosuppression in myeloproliferative neoplasms (MPNs) and directly inhibit T-cell activation and proliferation. We previously identified spontaneous T-cell responses towards PD-L1 and ARG1 derived peptide ep...

Descripción completa

Detalles Bibliográficos
Autores principales: Grauslund, Jacob Handlos, Holmström, Morten Orebo, Martinenaite, Evelina, Lisle, Thomas Landkildehus, Glöckner, Hannah Jorinde, El Fassi, Daniel, Klausen, Uffe, Mortensen, Rasmus E. J., Jørgensen, Nicolai, Kjær, Lasse, Skov, Vibe, Svane, Inge Marie, Hasselbalch, Hans Carl, Andersen, Mads Hald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996128/
https://www.ncbi.nlm.nih.gov/pubmed/36911725
http://dx.doi.org/10.3389/fimmu.2023.1117466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996128/
https://www.ncbi.nlm.nih.gov/pubmed/36911725
http://dx.doi.org/10.3389/fimmu.2023.1117466

Ejemplares similares